March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Defining Progression Using 10-2 Visual Field Tests in Treated Glaucoma
Author Affiliations & Notes
  • Christian E. Song
    Department of Ophthalmology, New York University School of Medicine, New York, New York
  • Carlos G. De Moraes
    Department of Ophthalmology, New York University School of Medicine, New York, New York
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
  • Joseph L. Simonson
    Department of Ophthalmology, New York University School of Medicine, New York, New York
  • Jeffrey Liebmann
    Department of Ophthalmology, New York University School of Medicine, New York, New York
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
  • Robert Ritch
    Einhorn Clinical Research Center, New York Eye and Ear Infirmary, New York, New York
    Department of Ophthalmology, New York Medical College, New York, New York
  • Footnotes
    Commercial Relationships  Christian E. Song, None; Carlos G. De Moraes, None; Joseph L. Simonson, None; Jeffrey Liebmann, Alcon Laboratories, Inc. (C), Allergan, Inc. (C), Carl Zeiss Meditec, Inc. (C), Dyopsis, Inc. (F, C), Merz, Inc. (C), Pfizer, Inc. (C), Quark, Inc. (C), Topcon Medical Systems, Inc. (F), Topcon Medical Sytems, Inc. (C); Robert Ritch, Aeon Astron (C), Drais Pharmaceutical (C), Dyopsis, Inc. (F), iSonic (C), Medacorp (C), Ocular Instruments, Inc. (C), Topcon Medical Systems, Inc. (F)
  • Footnotes
    Support  Susan and David Kahn Research Fund of the New York Glaucoma Research Institute, New York, NY.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 229. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christian E. Song, Carlos G. De Moraes, Joseph L. Simonson, Jeffrey Liebmann, Robert Ritch; Defining Progression Using 10-2 Visual Field Tests in Treated Glaucoma. Invest. Ophthalmol. Vis. Sci. 2012;53(14):229.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : No standardized criteria to define progression using 10-2 visual field (VF) tests in glaucoma management currently exist. We investigated the performance of potential progression criteria for 10-2 VF tests using trend analysis.

Methods: : We reviewed the 10-2 VF results of patients with severe glaucoma (24-2 VF MD < –12 dB) who performed ≥5 tests during follow-up. Global (MD and PSD) and localized (pointwise) rates of VF change (dB/yr) were calculated using linear regression providing slopes and P-values for each measured outcome based on 10-2 results. Progression (sensitivity) was defined using different combinations of steepness and P-values for the slopes, whereas false-positive results (1–specificity) were defined using the same criteria as those for progression but using positive slopes (i.e., VF "improvement"). For example, for a progression criterion with a slope <–1.0 dB/yr at P <0.05, a false-positive result was defined as >+1.0 dB/yr at P <0.05. The criterion with a combination of slopes and P-values leading to the highest likelihood ratio (LR= sensitivity/1–specificity) was deemed the one with best performance.

Results: : We included 178 eyes of 146 patients with a mean of 10.6±7.7 10-2 VF tests spanning 8.3±4.6 years. The mean baseline 10-2 MD and PSD values were –12.1±7.8 and 8.5±4.2 dB, respectively. The average rates of 10-2 MD and PSD change over time were –0.52±0.7 and +0.13±0.4 dB/yr, respectively. When defining progression based on the presence of at least one VF location progressing <–1.0 dB/yr at P <0.01, 130 (73%) eyes were deemed as progressing with 40 (22%) false-positive results (LR=3.3). Using the same definition but requiring the presence of at least 2 VF locations in the same arcuate region of a hemifield ("comma-shaped") defect, 99 (55%) eyes progressed with 19 (10%) false-positives (LR=5.5). All other tested criteria lead to smaller LR values than the ones above.

Conclusions: : In eyes with severe glaucoma, clinically significant VF deterioration in the central 10 degrees can be accurately detected using trend analysis. This is the first study to investigate progression criteria for 10-2 VFs using rates of change and to test their performance. These findings may be useful for monitoring glaucoma patients with severe functional loss.

Keywords: visual fields 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×